Cisplatin in cancer treatment

AMP Romani - Biochemical pharmacology, 2022 - Elsevier
Cisplatin is a widely used chemotherapy agent in the treatment of various forms of
carcinomas and sarcomas. Its effectiveness in delaying negative outcome in cancer patients …

The rediscovery of platinum-based cancer therapy

S Rottenberg, C Disler, P Perego - Nature Reviews Cancer, 2021 - nature.com
Platinum (Pt) compounds entered the clinic as anticancer agents when cisplatin was
approved in 1978. More than 40 years later, even in the era of precision medicine and …

[HTML][HTML] Introduction to traditional medicine and their role in prevention and treatment of emerging and re-emerging diseases

SAA Rizvi, GP Einstein, OL Tulp, F Sainvil, R Branly - Biomolecules, 2022 - mdpi.com
Infectious diseases have been a threat to human health globally. The relentless efforts and
research have enabled us to overcome most of the diseases through the use of antiviral and …

The DNA damage response to transcription stress

H Lans, JHJ Hoeijmakers, W Vermeulen… - … reviews Molecular cell …, 2019 - nature.com
The spatiotemporal control of RNA polymerase II (Pol II)-mediated gene transcription is
tightly and intricately regulated. In addition, preservation of the integrity of the DNA template …

Metal drugs and the anticancer immune response

B Englinger, C Pirker, P Heffeter, A Terenzi… - Chemical …, 2018 - ACS Publications
The immune system deploys a multitude of innate and adaptive mechanisms not only to
ward off pathogens but also to prevent malignant transformation (“immune surveillance”) …

Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment

L Kang, Y Tian, S Xu, H Chen - Journal of Neurology, 2021 - Springer
Oxaliplatin (OXA) is a commonly used platinum-based chemotherapy drug for colorectal
cancer. OXA-induced peripheral neurotoxcity (OIPN) is a comprehensive adverse reaction of …

Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors

J García-Foncillas, Y Sunakawa, D Aderka… - Frontiers in …, 2019 - frontiersin.org
Cetuximab and panitumumab are two distinct monoclonal antibodies (mAbs) targeting the
epidermal growth factor receptor (EGFR), and both are widely used in combination with …

[HTML][HTML] Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents

NAG Dos Santos, RS Ferreira… - Food and chemical …, 2020 - Elsevier
Cisplatin has dramatically improved the survival rate of cancer patients, but it has also
increased the prevalence of hearing and neurological deficits in this population. Cisplatin …

Chemotherapy-induced peripheral neuropathy: Current status and progress

JR Brewer, G Morrison, ME Dolan, GF Fleming - Gynecologic oncology, 2016 - Elsevier
As there are increasing numbers of cancer survivors, more attention is being paid to the long
term unwanted effects patients may experience as a result of their treatment and the impact …

[HTML][HTML] Long-term toxicity of cisplatin in germ-cell tumor survivors

M Chovanec, MA Zaid, N Hanna, N El-Kouri… - Annals of …, 2017 - Elsevier
Context Testicular germ-cell tumors (GCT) are highly curable. A multidisciplinary approach,
including cisplatin-based chemotherapy has resulted in cure in the majority of patients with …